Literature DB >> 10844095

Kinetic characterization of the nitric oxide toxicity for PC12 cells: effect of half-life time of NO release.

T Yamamoto1, K Yuyama, K Nakamura, T Kato, H Yamamoto.   

Abstract

We investigated the effects of low concentrations of nitric oxide (NO) on cell viability using NO donors, (+/-)-(E)-4-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hex enamid e (NOR1), (+/-)-(E)-4-methyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide (NOR2), (+/-)-(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide (NOR3) and (+/-)-N-[(E)-4-ethyl-2-[(Z)-hydroxyimino]-5-nitro-3-hexen-1- yl]-3-pyr idine (NOR4). The half-life times of the NO release from these four NOR analogs, NOR1, NOR2, NOR3 and NOR4, were determined (6.5, 84, 105 and 340 min, respectively) by using 4,5-diaminofluorescein (DAF-2), a newly developed indicator of NO. Exposure of undifferentiated PC12 cells to low concentrations of NO donors, NOR2 or NOR3 (1-100 microM), but not NOR1 nor NOR4, resulted in cell death in a dose- and time-dependent manner, as determined from cell viability assessed by 3-(4,5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium (MTT) assay. After 24 h exposure to 50 microM NOR2 or NOR3, more than 90% of PC12 cells had died. Furthermore, while the toxic effect of NOR3 was attenuated by replacing the medium at 20 min, 1 or 2 h after drug addition, it was continued by replacing the medium at 3 h or later after drug addition. The cell death was characterized by DNA degradation, nuclear condensation and fragmentation, suggesting apoptosis-like cell death. Pretreatment with an antioxidant ascorbic acid (0.1-0.5 mM) completely prevented the cell death caused by NOR3, while glutathione (0.1-0.2 mM) and cysteine (0.2-0.4 mM) provided partial protection. These findings suggest that the cell toxicity induced by NO at low concentrations strongly depends upon the duration of expose to NO from NO donors, and these toxic effects are effectively prevented by the antioxidant, ascorbic acid.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10844095     DOI: 10.1016/s0014-2999(00)00244-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Nitric oxide and cGMP protein kinase (cGK) regulate dendritic-cell migration toward the lymph-node-directing chemokine CCL19.

Authors:  Daniela Giordano; Dario M Magaletti; Edward A Clark
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

2.  Hypothermia at 35 °C reduces the time-dependent microglial production of pro-inflammatory and anti-inflammatory factors that mediate neuronal cell death.

Authors:  Tomohiro Matsui; Yusuke Yoshida; Masashi Yanagihara; Hiromi Suenaga
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

3.  CD81 inhibits the proliferation of astrocytes by inducing G(0)/G (1) arrest in vitro.

Authors:  Junfang Ma; Rengang Liu; Huiming Peng; Jieping Zhou; Haipeng Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-04-21

4.  The neuroprotective effects of ginsenosides on calcineurin activity and tau phosphorylation in SY5Y cells.

Authors:  Ling-Hui Tu; Jie Ma; Hai-Peng Liu; Rong-Rong Wang; Jing Luo
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

5.  Effect of melatonin and melatonylvalpromide on beta-amyloid and neurofilaments in N2a cells.

Authors:  Xiao-Chuan Wang; Yin-Chun Zhang; Nithiananda Chatterjie; Inge Grundke-Iqbal; Khalid Iqbal; Jian-Zhi Wang
Journal:  Neurochem Res       Date:  2008-01-31       Impact factor: 3.996

6.  Effect of bradykinin on nitric oxide production, urea synthesis and viability of rat hepatocyte cultures.

Authors:  Settimio Sesti; Guglielmo Martino; Sergio Mazzulla; Rosa Chimenti
Journal:  BMC Physiol       Date:  2005-01-25

7.  Synthesis of Nitric Oxide Donors Derived from Piloty's Acid and Study of Their Effects on Dopamine Secretion from PC12 Cells.

Authors:  Daniele Sanna; Gaia Rocchitta; Maria Serra; Marcello Abbondio; Pier Andrea Serra; Rossana Migheli; Lidia De Luca; Eugenio Garribba; Andrea Porcheddu
Journal:  Pharmaceuticals (Basel)       Date:  2017-09-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.